Akash Mukherjee

Researcher

UAMS
Last publication 2025 Last refreshed 2026-05-16

faculty

9 h-index 69 pubs 272 cited

Research Areas

Links

ORCID Research Group

OverviewAI-generated summary

Akash Mukherjee's research focuses on hematologic malignancies, particularly acute lymphoblastic leukemia (ALL) and its treatment. His work investigates outcomes and insights from real-world data for patients receiving brexucabtagene autoleucel, a CAR T-cell therapy for relapsed/refractory B-cell ALL. Mukherjee has also explored the impact of prior treatments, such as inotuzumab ozogamicin, on the effectiveness of CAR T-cell therapy.

His research also includes understanding and mitigating complications associated with hematopoietic stem cell transplantation. This includes studying immune effector cell-associated HLH-like syndrome and the role of specific bacteria, like Bacteroides ovatus, in alleviating graft-versus-host disease, particularly in the intestinal tract. Mukherjee collaborates with several researchers at the University of Arkansas for Medical Sciences, including Muthu Veeraputhiran, Ankur Varma, Mamatha Gaddam, and Manojna Konda.

Metrics

  • h-index: 9
  • Publications: 69
  • Citations: 272

Selected Publications

  • The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (2025)
    1 citation DOI OpenAlex
  • Gut Microbiome Diversity and Composition Changes Post Allogeneic Hematopoietic Stem Cell Transplant (AlloSCT): A Single-Center Prospective Analysis (2024)
    DOI OpenAlex
  • The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2024)
    DOI OpenAlex
  • Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care (2024)
    5 citations DOI OpenAlex
  • Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy (2024)
    4 citations DOI OpenAlex
  • Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (2023)
    4 citations DOI OpenAlex
  • Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (2023)
    14 citations DOI OpenAlex
  • The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2023)
    1 citation DOI OpenAlex
  • Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study (2023)
    1 citation DOI OpenAlex
  • Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) (2023)
    4 citations DOI OpenAlex
  • The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2023)
    4 citations DOI OpenAlex
  • Interdigitating Dendritic Cell Sarcoma and Indeterminate Dendritic Cell Tumor: Patient Characteristics, Prognostic Factors, and Survival Outcomes for Rare Dendritic Cell Neoplasms (2023)
    DOI OpenAlex
  • Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity (2023)
    25 citations DOI OpenAlex
  • Epidemiology of Aggressive NK-Cell Leukemia in the United States: A SEER Population-Based Study (2021)
    3 citations DOI OpenAlex
  • Clinical Outcome of Refractory Lymphoma Patients with Non Response to Chimeric Antigen Receptor T Cell Therapy (2021)
    DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

206 Collaborators 74 Institutions 5 Countries

Top Collaborators

Similar Researchers

Based on overlapping research topics

Muthu Veeraputhiran University of Arkansas for Medical Sciences
CAR-T cell therapy research Acute Lymphoblastic Leukemia research Hematopoietic Stem Cell Transplantation
Good match 5 shared topics
Jaskirat Sethi University of Arkansas for Medical Sciences
CAR-T cell therapy research Hematopoietic Stem Cell Transplantation Immune Response and Inflammation
Good match 4 shared topics
Ruud Dings University of Arkansas for Medical Sciences
CAR-T cell therapy research Immune Response and Inflammation Cancer Treatment and Pharmacology
Good match 4 shared topics
Lauren Appell University of Arkansas for Medical Sciences
CAR-T cell therapy research Hematopoietic Stem Cell Transplantation Immune Response and Inflammation
Good match 4 shared topics
A Almashayekh University of Arkansas for Medical Sciences
CAR-T cell therapy research Hematopoietic Stem Cell Transplantation Immune Response and Inflammation
Good match 4 shared topics
Cade Richesin University of Arkansas at Fayetteville
CAR-T cell therapy research Hematopoietic Stem Cell Transplantation Immune Response and Inflammation
Good match 4 shared topics